PIROXICAM YANG DIDUGA SEBAGAI AGEN PENYEBAB STEVEN-JOHNSON SYNDROME : SEBUAH LAPORAN KASUS
DOI:
https://doi.org/10.29303/jku.v10i4.627Abstract
Steven-Johnson Syndrome (SJS) is an acute mucocutaneous reaction characterized by extensive necrosis and exfoliation of the epidermal layer. The most common etiology or trigger in SJS cases is drugs or their metabolites, followed by infection and idiopathic. The most common drugs that trigger SJS include sulfonamides, non-steroidal anti-inflammatory drugs (NSAIDs) such as oxicam derivatives, imidazole antifungals, cephalosporins, anticonvulsants, allopurinol, broad-spectrum bactericidal agents, and the regimen. Highly Active Anti Retroviral Therapy (HAART). A 42-year- old woman with complaints of blisters on the lips and eyelids and red spots on the body, hands and feet. These complaints began to arise after the patient took the drug Piroxicam. The lesions on the forehead, eyelids, lips and neck in the form of erythematous macular-patch lesions, irregular in shape, poorly demarcated, with lenticular-plaque size, discrete-confulnous arrangement, regional distribution accompanied by erosions and hemorrhagic crusts. lesions on the abdomen, hands and feet in the form of macules – erythematous patches with purpura in the central part, round andin shape irregular, with miliary-plaque size, with discrete-confluent arrangement and generalized distribution with blackish brown erosions and crusts on the left upper quadrants of the abdomen, erosions and hemorrhagic crusts on the left upper arm. The patient was diagnosed with Steven- Johnson Syndrome who later died from aspiration on day 9. The presence of precipitating factors and skin and mucosal lesions that lead to SJS can speed up clinical decision making so that treatment is given more quickly.
References
2. Miya, R., Malpani, A.K., Keri, S., Panagaon, R. Drug Induced Steven- Johnson Syndrome (SJS). Indian Journal of Pharmacy Practice. 2019; Vol.
12.
3. de Guido, C., Calderaro, A., Ruozi, M.B., Maffini, V., Varini, M., Lapetina, I., Rubini, M., Montecchini, S., Caffarelli, C. and Dodi, I. An Unusual Cause Of Steven-Johnson Syndrome. ACTA Biomedica Journal. 2020.
4. Yang, S.-C., Hu, S., Zhang, S.-Z., Huang, J., Zhang, J., Ji, C., & Cheng, B.
The Epidemiology of Stevens-Johnson Syndrome and Toxic Epidermal
Necrolysis in China. Journal of Immunology Research, 2018.
5. Lee, H. Y., Martanto, W., & Thirumoorthy, T. Epidemiology of Stevens– Johnson syndrome and toxic epidermal necrolysis in Southeast Asia. Dermatologica Sinica Journal. 2013; 31(4), 217–220.
6. Wong, A., Malvestiti, A. A., & Hafner, M. de F. S. Stevens-Johnson syndrome and toxic epidermal necrolysis: a review. Revista Da Associação Médica Brasileira Journal. 2016; 62(5), 468–473.
7. Blumenthal, KG. “Stevens-Johnson syndrome and toxic epidermal necrolysis: a cross-sectional analysis of patients in an integrated allergy repository of a large health care system. The journal of allergy and clinical immunology In practice. 2016; vol. 3,2 2015: 277-280.e1.
8. Patel, T., Barvaliya, M., Sharma, D., & Tripathi, C. A systematic review of the drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Indian population. Indian Journal of Dermatology, Venereology, and Leprology. 2013; 79(3), 389.
9. Diana, R., Rahayu, T., Eka, P.W., and Irawanto, M.E. Pathophysiology and Management of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. J Gen Proced Dermatol Venereol Indones Journal. 2020;
5(1);28-39
10. Creamer, D., Walsh, S. A., Dziewulski, P., Exton, L. S., Lee, H. Y., Dart, J.
K. G., Smith, C. H.. U.K. Guidelines for the Management of Stevens- Johnson Syndrome/Toxic Epidermal Necrolysis in Adults 2016. British Journal of Dermatology. 2016;174(6), 1194–1227.
11. Gupta, L.K., Martin, A.M., Agarwal, N., D’Souza, P., Das, S., Kumar, R., Pande, S., Das, N.K., Kumaresan, M., Kumar, P., Garg, A., and Singh, S. (2016). Guidelines for the management of Stevens–Johnson syndrome/toxic epidermal necrolysis: An Indian perspective. Indian Journal of Dermatology, Venerology, and Leprology, 82(6), 603 – 625
12. Raffaele, R.M., de Oliveira, R.L., Baldo, M.E., Santana, G.U., Pacheco, J.A.
Treatment of Low Level Laser Therapy in the Oral Manifestations of Steven
Johnson Syndrome. J Intern Med Emerg Res Journal. 2020; 1(3):1-8.
13. Deore, S.S., Dandekar, R.C., Mahajan, A.M., Shiledar, V.V. Drug Induced
- Stevens Johnson Syndrome: A Case Report. Int J Sci Stud Journal.
2014;2(4):84-87
14. Fakoya, A. O. J., Omenyi, P., Anthony, P., Anthony, F., Etti, P., Otohinoyi, D. A., & Olunu, E. Stevens - Johnson Syndrome and Toxic Epidermal Necrolysis; Extensive Review of Reports of Drug-Induced Etiologies, and Possible Therapeutic Modalities. Open Access Macedonian Journal of Medical Sciences. 2018; 6(4), 730–738.
15. Cheraghlou, S., & Levy, L. L. (2020). Fixed Drug Eruptions, Bullous Drug Eruptions, and Lichenoid Drug Eruptions. Clinics in Dermatology. Clinics in Dermatology Journal 2020.
16. Cho, Y.-T., Lin, J.-W., Chen, Y.-C., Chang, C.-Y., Hsiao, C.-H., Chung, W.-H., & Chu, C.-Y. Generalized bullous fixed drug eruption is distinct from Stevens-Johnson syndrome/toxic epidermal necrolysis by immunohistopathological features. Journal of the American Academy of Dermatology. 2014; 70(3), 539–548.
17. Newkirk, R. E., Fomin, D. A., & Braden, M. M. Erythema Multiforme Versus Stevens–Johnson Syndrome/Toxic Epidermal Necrolysis: Subtle Difference in Presentation, Major Difference in Management. Military Medicine oxford Academic Journal. 2020.
18. Zavala, S., O’Mahony, M., Joyce, C., & Baldea, A. J.. How Does
SCORTEN Score?. Journal of Burn Care & Research. 2017; 39(4), 555–
561.
19. Clayton, N. A., Ward, E. C., & Maitz, P. K. Intensive swallowing and orofacial contracture rehabilitation after severe burn: A pilot study and literature review. 2016; 43(1), e7–e17. doi:10.1016/j.burns.2016.07.006
